Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Halozyme Therapeutics, Inc. on May 5, 2021. The filing details the voting results for five proposals submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no values provided for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
As of the record date, the company had 143,301,550 shares of common stock outstanding. A total of 127,617,860 shares were represented at the meeting. All five proposals were approved by the stockholders:
- Proposal 1 (Director Election): Jean-Pierre Bizzari and James M. Daly were elected as Class I directors for a three-year term.
- Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved.
- Proposal 3 (2021 Stock Plan): The Halozyme Therapeutics, Inc. 2021 Stock Plan was approved.
- Proposal 4 (Employee Stock Purchase Plan): The Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan was approved.
- Proposal 5 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcomes of the shareholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement filed on March 26, 2021, for detailed descriptions of the approved proposals.
- Confirm the specific terms of the newly approved 2021 Stock Plan and Employee Stock Purchase Plan.
- Review the company's most recent 10-K or 10-Q filings for financial metrics not included in this 8-K.